Biomedical, Clinical & Life Sciences

No Applicants // Limit: 1 predoctoral applicant per lab

The PhRMA Foundation’s Predoctoral Fellowship in Translational Medicine supports promising students (U.S. and non-U.S. citizens) in advanced stages of training and thesis research in translational medicine.

Eligibility
Only one predoctoral applicant per lab may apply for this award. If multiple applicants apply, they will automatically be ineligible. Potential applicants and their thesis advisors and/or lab managers should decide who should apply.

For full eligibility criteria, please see the Translational Medicine Predoctoral Fellowship webpage.

No Applicants // Limit: 1 postdoctoral applicant per lab

The PhRMA Foundation’s Postdoctoral Fellowship in Translational Medicine supports individuals (U.S. and non-U.S. citizens) engaged in a multidisciplinary, collaborative research training program at an accredited U.S. university that will extend their credentials in translational medicine.

Eligibility
Only one postdoctoral applicant per lab may apply for this award. If multiple applicants apply, they will automatically be ineligible. Potential applicants and their thesis advisors and/or lab managers should decide who should apply.

For full eligibility criteria, please see the Postdoctoral Fellowships - Translational Medicine webpage.

Limit: 1 predoctoral applicant per lab

M. Ma (Hongmin Li Lab) 

The PhRMA Foundation Predoctoral Fellowship in Drug Discovery provides support for promising students (U.S. and non-U.S. citizens) in advanced stages of training and thesis research in drug discovery research.

Eligibility
Only one predoctoral applicant per lab may apply for this award. If multiple applicants apply, they will automatically be ineligible. Potential applicants and their thesis advisors and/or lab managers should decide who should apply.

For full eligibility criteria, please see the Drug Discovery Predoctoral Fellowship webpage. 

The University of Arizona is ineligible to apply to this cycle due to an existing proposal.

Limit: 1 // Tickets Available: 0 

J. Young (Nursing)

Eligibility

Purpose
The purpose of the Nursing Workforce Diversity (NWD) program is to increase nursing education opportunities for individuals who are from disadvantaged backgrounds (including racial and ethnic minorities underrepresented among registered nurses). The program uses comprehensive, evidence-based strategies to provide more inclusive and culturally aligned nursing education environments that will support students from disadvantaged backgrounds. Please refer to the Bureau of Health Workforce Glossary for program terms applicable to this Notice of Funding Opportunity (i.e., disadvantaged background, underrepresented minority).

Limit: 1 // Tickets Available: 1

Kenry (Pharmacology and Toxicology) 

The University of Arizona Cancer Center (UACC) can nominate one individual for the 2026 Pew-Stewart Scholars for Cancer Research program. For more information please contact: UACC-PreAward.

In line with The Stewart Trust’s mission to invest in innovative, cutting-edge cancer research that may accelerate and advance progress toward a cure for cancer, applications are invited from nominees conducting cancer research at NCI-designated cancer centers, or cancer-focused institutions. The Pew-Stewart Scholars Program for Cancer Research is distinct from the Pew Scholars Program, and it follows a different, but parallel set of guidelines and procedures for nominating an applicant whose research is related to cancer.

In early April 2025, a letter of invitation and application instructions will be sent to the leaders of the cancer research institutions selected to submit a nominee for the 2026 class. Centers are expected to complete a limited submission competition in order to identify and select one nominee. For guidance on this process, please contact Pew-Stewart@pewtrusts.org.

• Center administration should distribute this invitation and award eligibility details to all investigators via an email announcement or website posting.
• Interested applicants should submit pre-proposal material to an internal selection committee for consideration.
• To nominate a candidate, a member of the internal selection committee must complete an online survey from the Pew program office describing the selection process used by the institution and submit the name and contact information of the chosen applicant by May 14, 2025.
• Nominations of applicants to the program will not be considered after May 14, 2025.
• The Pew program office will email grant application portal login information and a detailed application guide directly to all nominated applicants by June 11, 2025. The online application website will open on June 11, 2025.
• For research administrators assisting an applicant, please send an email with your grant applicant cc’ed to Pew-Stewart@pewtrusts.org after June 11, 2025, to receive access to the portal. No requests will be accepted prior to this date.
• The application submission deadline is Aug. 27, 2025.
• Every application will be reviewed by the program's National Advisory Committee. The committee will make recommendations to the board of directors of The Pew Charitable Trusts in April 2026. Candidates will be notified in April if they have been recommended to the Stewart and Pew boards.
• A public announcement of the award will be made in June. Grant agreements will be issued to the grant hosting institution of each scholar in August of the award year.

No Applicants // Limit: 2 (1 Translational nominee, 1 All-Star Translational nominee) // Tickets Available: 2 

The University of Arizona Cancer Center (UACC) can nominate up to two proposals: one Translational nominee and one All-Star Translational nominee (if eligible) for the V Foundation Adult Translational Cancer Research Award 2025. 

For more information please contact: UACC-PreAward.

Purpose of Award:

The UACC is seeking nominations for the Translational Adult Cancer Research Grant which advances basic laboratory discoveries towards clinical use, ultimately improving human health and is restricted to adult cancer research.

This Translational grant is restricted to adult cancer research in the preclinical or translational space with a focus on bench-to-bedside strategies. Research on ANY adult cancer type can be funded. Applicants may propose cancer research that moves a novel strategy from the laboratory into a human clinical trial or uses specimens from a clinical trial to test hypotheses, develop biomarkers, or mechanisms. The research must apply in a direct way to human beings within 3 years from the end of the grant. If biomarker research is undertaken, a validation set or independent clinical trial is essential. A plan for biomarker validation, if applicable, must be included in any proposal. The endpoint of the project should be the planning or initiation of a new clinical trial or conducting an investigator-initiated trial with laboratory correlates that test hypotheses. Research areas not included in this scope are epidemiology, behavioral science, and health services research.

Limit: 1 per SIP

K. Ellingson (Public Health) for SIP25-005 Understanding the potential of early childcare and education (ECE) centers in promoting childhood vaccines and RSV prevention products

S. Carvajal (College of Public Health's Prevention Research Center) for SIP25-006 Overdose Prevention and Treatment Research Network (OPTRN)

Eligibility: 
Only one application per SIP per institution is allowed (e.g., multiple applications for the same SIP (listed in Section VIII) from the same institution are NOT permitted).

Purpose:
This Notice of Funding Opportunity (NOFO) invites applications from CDC Health Promotion and Disease Prevention Research Centers (PRCs), selected for funding under RFA-DP-24-004, to apply for supplemental funding to conduct Special Interest Research Projects (SIPs) to inform public health practice. PRCs will conduct high-quality applied health promotion and disease prevention research projects in real-world settings to identify, design, test, evaluate, disseminate, and translate interventions (i.e., programs, practices, policies, or strategies) to prevent and reduce risk for the leading causes of illness, disability, and death in the United States.

No Applicants // Limit: 2 // Tickets Available: 2

Number of Applications
The NIH will not accept duplicate or highly overlapping applications under review at the same time, per 2.3.7.4 Submission of Resubmission Application. This means that the NIH will not accept:

• A new (A0) application that is submitted before issuance of the summary statement from the review of an overlapping new (A0) or resubmission (A1) application.
• A resubmission (A1) application that is submitted before issuance of the summary statement from the review of the previous new (A0) application.
• An application that has substantial overlap with another application pending appeal of initial peer review (see 2.3.9.4 Similar, Essentially Identical, or Identical Applications).

Two applications per institution (with a Unique Entity Identifier ) and a unique NIH eRA Institutional Profile File (IPF) number) are allowed per review round. The same or a similar topic may be submitted for subsequent review rounds involving the same or a similar team, but must be presented as a New application, not a Resubmission.

Applications that are not considered to be within the NIGMS mission will not be reviewed. Eligibility and appropriateness to the NIGMS mission will be evaluated again after review and prior to funding. Applications outside the NIGMS mission will not be funded. Given that only two applications are permitted per institution per review round, it is important to contact NIGMS staff before committing to any particular team and its topic area.

Purpose: 
This Funding Opportunity Announcement (FOA) is designed to support highly integrated research teams of three to six Program Directors/Principal Investigators (PDs/PIs) to address ambitious and challenging research questions that are within the mission of NIGMS. Project goals should not be achievable with a collection of individual efforts or projects. Collaborative program teams are expected to accomplish goals that require considerable synergy and managed team interactions. Teams are encouraged to consider far-reaching objectives that will produce major advances in their fields.

This FOA is not intended for applications that are mainly focused on the creation, expansion, and/or maintenance of community resources, creation of new technologies, or infrastructure development.

Request Ticket // Limit: 4* (1 per grant type) // Tickets Available: 2

Legacy Researcher Grant // Limit 1 // Tickets Available: 1

Translational Research Grant // Limit: 1 // Tickets Available: 0
K. Huntoon (Neurosurgery) 

Emerging Investigator Fellowship Grant // Limit: 1 // Tickets Available: 0
S. Ganesh (Biomedical Engineering) 

Donor Designated Grant Program // Limit: 1 // Tickets Available: 1

Eligibility
Provide the name of the Institution, Principal Investigator and their title. An institution may only submit one LOI per award type. Multiple LOIs should not be submitted by the same researcher. 

Grant Categories 
The Pediatric Cancer Research Foundation awards four types of research grants: 

1. Legacy Researcher Grant (up to $100,000 per year, up to 2 years for translational research and up to $150,000 per year, for three years, for basic science research) 
   This grant is given to a long-standing PCRF-funded researcher for at least five years, who has demonstrated consistent progress and outcomes in pediatric cancer research. This funding category aims to support and sustain ongoing initiatives, ensuring that momentum is maintained on critical projects with potential for cures.  
2. Translational Research Grants (up to $100,000 per year, up to 2 years)  
   This grant is given to single or multi-institutional programs that involve open, cancer clinical trials or consortia, and implement new approaches to therapy. These grants support “bench to bedside” research, whose endpoint is often the planning or initiation of a clinical trial. 
3. Emerging Investigator Fellowship Grants (up to $75,000 for one year) 
   These grants are designed to support Post-Doctoral Fellowships and Clinical Investigator training for emerging pediatric cancer researchers to pursue exciting research ideas. Applicants must have completed two years of their fellowship or not more than two years as a junior faculty instructor or assistant professor at the start of the award period. These grants encourage and cultivate the best and brightest researchers of the future. 
4. Donor Designated Grant Programs 
   These grants fund projects in communities or regions local to the specific donor or fundraising activity. Outside contributing organizations, fundraisers and donors work with the Foundation to identify a specific project and/or specific doctor, focus on a specific disease type, facility or awareness program. Grants can be for any specific amount as designated by the donor or contributing organization. PCRF will not accept grant application without an approved Letter of Intent (LOI). Please refer to the guidelines contained in this document for the specific guidelines.